GlassScriptPhysician profile
Whitney S Denton
NPI 1235128455
$2,657.44
in general payments reported to CMS, 2019-2025
28 companies · $682 in 2025
The $682 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $175 · 2021: $375 · 2022: $318 · 2023: $365 · 2024: $543 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,589.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $688.92 | 2019-2025 | Vraylar, Synthroid |
| Novo Nordisk INC | $566.35 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $198.01 | 2019-2025 | |
| Astellas Pharma US INC | $190.82 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $167.76 | 2023-2025 | Shingrix, Arexvy, Flulaval Quadrivalent |
| Abbott Laboratories | $114.52 | 2022-2025 | Freestyle Libre 3 |
| Allergan, INC. | $98.92 | 2020 | |
| Dexcom, INC. | $89.34 | 2022-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $79.44 | 2021 | |
| Amgen INC. | $54.33 | 2019-2024 | Evenity, Prolia |
| Dynavax Technologies Corporation | $48.99 | 2024-2025 | Heplisav-B |
| Ibsa Pharma INC. | $40.98 | 2025 | Tirosint, Licart, Flector |
| Exact Sciences Corporation | $33.36 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $31.63 | 2025 | Symbravo |
| Currax Pharmaceuticals LLC | $29.00 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $27.71 | 2025 | General - Pain Management |
| Otsuka America Pharmaceutical, INC. | $23.48 | 2022 | |
| Inspire Medical Systems, INC. | $22.77 | 2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.82 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.03 | 2024 | |
| Biogen, INC. | $16.71 | 2025 | Leqembi |
| Optinose US, INC. | $15.65 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.63 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.25 | 2019 | |
| Amarin Pharma, INC. | $14.20 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.73 | 2019 | |
| Lilly USA, LLC | $13.70 | 2024 | Jardiance |
| Vivus LLC | $8.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Denton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.